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Abstract
Background: Little is known about the association between physical activity before cancer diagnosis and survival among
lung cancer patients. In this pooled analysis of 11 prospective cohorts, we investigated associations of prediagnosis leisuretime physical activity (LTPA) with all-cause and lung cancer–specific mortality among incident lung cancer patients.
Methods: Using self-reported data on regular engagement in exercise and sports activities collected at study enrollment, we
assessed metabolic equivalent hours (MET-h) of prediagnosis LTPA per week. According to the Physical Activity Guidelines
for Americans, prediagnosis LTPA was classified into inactivity, less than 8.3 and at least 8.3 MET-h per week (the minimum
recommended range). Cox regression was used to estimate hazard ratios (HRs) and 95% confidence interval (CIs) for all-cause
and lung cancer–specific mortality after adjustment for major prognostic factors and lifetime smoking history. Results: Of
20 494 incident lung cancer patients, 16 864 died, including 13 596 deaths from lung cancer (overall 5-year relative survival
rate ¼ 20.9%, 95% CI ¼ 20.3% to 21.5%). Compared with inactivity, prediagnosis LTPA of more than 8.3 MET-h per week was associated with a lower hazard of all-cause mortality (multivariable-adjusted HR ¼ 0.93, 95% CI ¼ 0.88 to 0.99), but not with lung
cancer–specific mortality (multivariable-adjusted HR ¼ 0.99, 95% CI ¼ 0.95 to 1.04), among the overall population. Additive interaction was found by tumor stage (Pinteraction ¼ .008 for all-cause mortality and .003 for lung cancer–specific mortality).
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When restricted to localized cancer, prediagnosis LTPA of at least 8.3 MET-h per week linked to 20% lower mortality: multivariableadjusted HRs were 0.80 (95% CI ¼ 0.67 to 0.97) for all-cause mortality and 0.80 (95% CI ¼ 0.65 to 0.99) for lung cancer–specific mortality. Conclusions: Regular participation in LTPA that met or exceeded the minimum Physical Activity Guidelines was
associated with reduced hazards of mortality among lung cancer patients, especially those with early stage cancer.

Methods
Study Populations
We harmonized de-identified, individual participant data from
11 cohorts (16,17), including 7 US cohorts (National Institute of
Health–American Association of Retired Persons Diet and
Health Study; Health Professionals Follow-up Study; Nurses’
Health Study; Iowa Women’s Health Study; Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial; Southern
Community Cohort Study; and VITamins And Lifestyle Study), 2
European cohorts (European Prospective Investigation into
Cancer and Nutrition and Trøndelag Health Study), and 2 Asian

cohorts (Shanghai Men’s Health Study and Shanghai Women’s
Health Study). All studies were approved by the institutional review boards and ethics committees of the hosting institutes.
Among 1 588 378 initial participants, we identified 22 762 incident lung cancer patients diagnosed after study enrollment.
Of those, we excluded individuals who had no data on LTPA
(n ¼ 2031), smoking history (n ¼ 183), and survival time (n ¼ 45).
Cancer in situ was also excluded (n ¼ 9), thus leaving 20 494
patients. Characteristics of each participating cohort and our
analytic sample are summarized in Table 1.

Assessment and Parameterization of LTPA Exposure
This study used LTPA data only, not incorporating other
domains of PA. Prediagnosis LTPA was assessed at baseline using validated cohort-specific questionnaires asking about regular engagement in exercise and sports activities (18-26). Details
of LTPA assessment in each cohort, including original questions, intensity, and exposure windows, are shown in
Supplementary Table 1 (available online). The level of LTPA was
quantified in metabolic equivalent hours per week (MET-h/
week), using the Compendium of Physical Activities (27). Based
on the Physical Activity Guidelines for Americans (12,28,29),
prediagnosis LTPA was classified into inactive, low active (>0 to
<8.3 MET-h/week), moderately active (the recommended level
for health benefits: 8.3-16.0 MET-h/week, equivalent to 150300 minutes of moderate or 75-150 minutes of vigorous intensity
activity per week), and highly active (>16.0 MET-h/week).
Because of the limited number of study participants in the
highly active group, this group was finally combined with the
moderately active group, referred to as met or exceeded the
minimum recommendation (8.3 MET-h/week).

Assessment of Outcome
Each cohort has followed-up cancer incidence and mortality via
linkages to national and regional registries, follow-up surveys,
medical record reviews, or a combination of these methods.
Incident lung cancer patients were ascertained using the
International Classification of Diseases 9th or 10th revision (162 and
C34, respectively). All patients were subclassified by histological
type (adenocarcinoma, squamous cell carcinoma, other nonsmall cell carcinoma, small cell carcinoma, or unspecified or
unknown), stage (localized [stage I/II], regional [stage III], distant
[stage IV], and unknown), and grade (well, moderately, and
poorly differentiated; undifferentiated; and unknown). For deceased ones, we obtained information on the underlying cause
and date of death. Survival time was calculated as total years
from the date of lung cancer diagnosis to the date of death,
loss-to-follow-up, or end of follow-up, whichever occurred first.

Covariates
Potential confounders were selected a priori based on literature
review and risk factors found in our study populations (16,17).
Included were age at diagnosis (continuous), sex, race and
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Lung cancer is the most common cancer in the world and
accounts for approximately 2.09 million new cases and 1.76 million deaths in 2018 (1). Despite the recent advances in lung cancer screening and treatments, more than half of newly
diagnosed patients die within a year of diagnosis; the overall 5year survival rate of lung cancer remains under 20% worldwide
(2,3). To reduce the global burdens of lung cancer, it is crucial to
identify potential risk and prognostic factors apart from smoking cessation.
Physical activity (PA) has attracted great attention in cancer
research because of its benefits in reducing inflammation, regulating hormones (eg, insulin), and improving immune function
and energy balance (4-6). Epidemiological evidence to date supports a link of PA to cancer prevention and survival (7-11). The
Physical Activity Guidelines Advisory Committee and the
American College of Sports Medicine Roundtable have recently
concluded that PA prevents at least 7 cancers (eg, breast and colon) and might confer survival benefits to patients with breast,
colon, and prostate cancers (8,9,11,12). Yet, evidence on PA and
lung cancer remains moderate or limited, especially for survival
outcomes (ie, all-cause and lung cancer–specific mortality)
(8,9,11,12). Although a recent meta-analysis and some prospective studies have shown a statistically significant reduction in
lung cancer mortality attributed to prediagnosis PA (7,13-15),
most of these studies had a small sample size. They are also
limited by residual confounding because of smoking and lack of
consideration of major prognostic factors and are unable to address subgroup variations. Large-scale, population-based prospective investigations that overcome previous limitations are
needed to fill a research gap and provide convincing evidence.
To this end, this pooled analysis of 11 cohorts from the
United States (US), Europe, and Asia aims to investigate associations of prediagnosis leisure-time PA (LTPA) with all-cause and
lung cancer–specific mortality among more than 20 000 incident
primary lung cancer patients. Given the substantial difference
in survivorship across lung cancer stage (2,3), analyses were
conducted in the overall study population and subgroups defined by tumor stage. Furthermore, we assessed effect modification by established prognostic factors (ie, stage, histology, and
grade), time interval from LTPA assessment to cancer diagnosis
(given possible measurement errors or biologically relevant
time windows), lifetime smoking history, and other risk factors.

2081 (1666)
432 (NA)

706 (684)
570 (531)
16 864 (13 596)

2540
474

918
826
20 494

2002-2015
1997-2015
1986-2015

1992-2009
1995-2011

1995-2007
1986-2009
1986-2009
1986-2012
1995-2010
2002-2013
2000-2012

Year of
diagnosis

5.8 (3.2-8.3)
10.2 (6.2-13.5)
7.1 (3.5-9.5)

7.1 (4.0-9.7)
8.4 (4.8-11.6)

5.5 (2.9-8.1)
12.4 (6.8-17.4)
13.9 (8.6-18.9)
12.8 (7.0-18.8)
7.5 (4.8-9.3)
3.6 (1.9-5.7)
5.2 (0.2-11.4)

Median time
intervals (IQR), yc

67.0 (9.5)
67.2 (9.0)
68.5 (7.6)

64.9 (8.0)
68.9 (10.5)

68.8 (5.5)
72.9 (8.8)
69.4 (7.7)
73.9 (7.5)
71.2 (6.1)
60.2 (8.7)
71.1 (7.1)

Mean age at
diagnosis (SD), y

30.3
26.4
42.6

81.5
25.5

39.2
51.5
40.4
41.9
34.1
17.2
32.7

Meet the
guideline, %d

0.0 (0.0-11.2)
0.0 (0.0-8.4)
4.5 (0.7-15.0)

22.5 (12.0-42.0)
3.4 (2.3-8.6)

4.5 (0.3-10.5)
8.8 (2.8-22.1)
5.2 (2.0-15.2)
8.2 (0.8-24.8)
4.5 (0.7-12.6)
0.0 (0.0-0.1)
3.3 (0.2-11.4)

Median LTPA
(IQR), MET-h/week

0.0
100.0
46.3

45.4
40.7

36.9
0.0
100.0
100.0
49.9
46.3
45.7

Women, %

85.8
8.0
88.0

90.0
94.1

93.1
88.8
90.8
82.3
89.6
94.8
92.5

Smokers, %e

87.1
99.0
84.1

81.0
80.0

83.5
85.3
83.9
79.7
90.0
84.6
86.1

NSCC, %

16.5 (14.1 to 19.1)
26.0 (22.9 to 29.2)
20.9 (20.3 to 21.5)

15.0 (13.6 to 16.5)
10.4 (7.85 to 13.4)

20.1 (19.3 to 20.9)
22.5 (20.0 to 25.2)
27.3 (25.0 to 29.6)
16.1 (13.9 to 18.4)
53.8 (49.5 to 57.9)
18.9 (16.1 to 21.8)
21.1 (18.6 to 23.8)

5-year survival
Rate (95% CI), %

Including primary lung cancer patients who were eligible for the current pooled analysis. AARP ¼ National Institute of Health–American Association of Retired Persons Diet and Health Study; CI ¼ confidence interval; EPIC ¼

8407 (6615)
885 (812)
1257 (1171)
914 (741)
263 (237)
585 (481)
764 (658)

No. of
deathsb

9684
983
1542
1017
666
815
1029

No. of
casesa

Number of deaths from all causes (deaths from lung cancer).

e

Percentage of adherence to the minimum recommended range of the Physical Activity Guidelines at least 500 MET-min (8.3 MET-h) per week.
Including current and former smokers.

d

Years from leisure-time physical activity assessment to lung cancer diagnosis.
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c

b

ical activity; MET-h/week ¼ metabolic equivalent hours per week; NHS ¼ Nurses’ Health Study; NSCC ¼ non-small cell carcinoma; PLCO ¼ Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SCCS ¼ Southern Community
Cohort Study; VITAL ¼ VITamins And Lifestyle Study; SMHS ¼ Shanghai Men’s Health Study; SWHS ¼ Shanghai Women’s Health Study.

European Prospective Investigation into Cancer & Nutrition; HPFS ¼ Health Professionals Follow-up Study; HUNT ¼ Trøndelag Health Study; IQR ¼ interquartile range; IWHS ¼ Iowa Women’s Health Study; LTPA ¼ leisure-time phys-

a

USA
AARP
HPFS
NHS
IWHS
PLCO
SCCS
VITAL
Europe
EPIC
HUNT
Asia
SMHS
SWHS
Total

Cohorts

Table 1. Participating cohorts included in the pooled analysis of prediagnosis leisure-time physical activity and lung cancer survival
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Statistical Analysis
Using the life-table method and log-rank test, we assessed 5year relative survival rates by baseline characteristics and clinical features of cancer. Cox proportional hazard regression was
used to estimate multivariable-adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) for all-cause and lung cancer–
specific mortality, using inactivity as the reference. The global
goodness-of-fit test with Schoenfeld residuals found no violation of the proportional hazard assumption. For lung cancer–
specific mortality, death from other causes was treated as a
competing risk. Given inter- and intrastudy variability, Cox
models were stratified by cohort, calendar years of lung cancer
diagnosis, and time interval between LTPA assessment and diagnosis. A random-effects meta-analysis was complimented
with I2 and Pheterogeneity to offset potential concerns of residual
heterogeneity.
Stratified analyses were conducted by major prognostic and
risk factors; to avoid reverse causality due to high fatality and
short survival time of distant stage cancer, these analyses were
restricted to early stage lung cancer. Additive interactions were
evaluated by the relative excess risk due to interaction (30,31),
referring to the excess risk from interaction between prediagnosis LTPA and stratification variables as compared with baseline

risk without exposure. P values were corrected for multiple
comparisons by controlling the false-discovery rate. A series of
sensitivity analyses were conducted using another LTPA categorization (cohort- and sex-specific quartiles and common quartiles across total participants), excluding participants with long
time intervals between LTPA assessment and cancer diagnosis
(over median years), further adjusting for dietary calcium intake
statistically significantly associated with lung cancer survival in
our populations (16), and excluding 1 cohort at a time from analyses. All procedures were performed using SAS 9.4 (SAS
Institute, Inc, Cary, NC), and 2-sided P-values less than .05 were
considered statistically significant.

Results
Of the 20 494 incident lung cancer patients, 16 864 patients died,
including 13 596 deaths from lung cancer (Table 1); the median
survival time was 0.9 years (interquartile range ¼ 0.3-2.7). The
mean age at lung cancer diagnosis was 68.5 years. Most patients
were ever-smokers (ranging from 82.3% to 94.8% across studies),
except for those from the Shanghai Women’s Health Study.
About 43% of patients met the minimum recommendation before lung cancer diagnosis. The overall 5-year survival rate was
20.9% (95% CI ¼ 20.3% to 21.5%).
Five-year relative survival rates were higher among patients
with high educational attainment, noncurrent smokers, smokers with less than 30 pack-years, nondiabetic patients, and
women taking hormone therapy (all P < .05); those patients also
showed higher proportions of meeting the guidelines. When
stratified by histological type, stage, and grade, we observed
much lower 5-year survival rates for small cell carcinoma
(10.0%), distant stage carcinoma (5.9%), and undifferentiated
lung carcinoma (11.8%) (Table 2).
Compared with inactivity (Table 3), LTPA of 8.3 MET-h/week
or more before cancer diagnosis was associated with a lower
hazard of all-cause mortality among the overall population
(HR ¼ 0.93, 95% CI ¼ 0.88 to 0.99), but not with lung cancer–specific mortality (HR ¼ 0.99, 95% CI ¼ 0.95 to 1.04), after adjustment
for all potential covariates. No heterogeneity was observed
across cohorts (Pheterogeneity ¼ .41 for all-cause and .28 for lung
cancer–specific mortality), with comparable HRs from randomeffects meta-analyses of 0.95 (95% CI ¼ 0.90 to 1.00) and 1.00
(95% CI ¼ 0.95 to 1.05), respectively (Supplementary Figures 1

Table 2. Leisure-time physical activity and 5-year survival rates among lung cancer patients by baseline characteristics

Characteristics
Age at diagnosis, y
<70
70
Sex
Men
Women
Race and ethnicity
Asian
Black
Other
White
Education
High school

No. of cases

No. of deaths

5-year survival

Meet the
guideline, (%)a

Median LTPA
(IQR) MET-h/week

Rate (95% CI), %

Pb

10 718
9776

8659
8205

41.4
44.0

4.5 (0.3-15.0)
4.9 (0.9-15.0)

22.3 (21.5 to 23.1)
18.9 (18.2 to 19.7)

<.001

11 010
9484

9384
7480

45.2
39.7

4.5 (1.0-15.0)
4.5 (0.4-15.0)

17.8 (17.1 to 18.6)
24.1 (23.2 to 25.0)

<.001

1852
954
219
17469

1356
716
186
14606

29.7
25.3
32.0
45.1

0.0 (0.0-10.5)
0.3 (0.0-9.2)
2.2 (0.3-10.5)
5.2 (1.5-15.0)

21.3 (19.4 to 23.3)
21.8 (19.1 to 24.5)
16.9 (12.2 to 22.2)
20.7 (20.1 to 21.3)

.02

8552

7091

39.6

4.5 (0.3-15.0)

18.4 (17.5 to 19.2)

<.001

(continued)
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ethnicity (Asian, Black, Other [Hispanic and Latino, American
Indian, and other racial or ethnic group] and White), smoking
status (never, former, current), smoking pack-years (continuous), education (less than high school, high school graduation,
vocational education, college, university or higher), alcohol consumption (none, moderate drinking up to 1 and 2 drinks per
day, heavy drinking >1 and >2 drinks per day for women and
men, respectively; 1 drink ¼ 14 grams of ethanol), history of diabetes (yes, no), body mass index (BMI; <18.5, 18.5-24.9, 25.0-29.9,
and 30.0 kg/m2), and hormone therapy in women (yes, no)—all
of which were assessed at LTPA assessment. Missing covariates
were independently imputed by cohort (16). Established prognostic factors were further included: tumor stage (localized, regional, distant, unknown), histological type (adenocarcinoma,
squamous cell carcinoma, other non-small cell carcinoma,
small cell carcinoma, unspecified or unknown), and grade (well,
moderately, and poorly differentiated; undifferentiated;
unknown).
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Table 2. (continued)

Characteristics

No. of deaths

Median LTPA
(IQR) MET-h/week

Rate (95% CI), %

Pb

6662
5280

5441
4332

41.5
49.0

4.5 (1.5-12.2)
7.7 (1.5-15.0)

21.7 (20.7 to 22.7)
23.2 (22.1 to 24.4)

2457
8233
9804

1760
6875
8229

46.0
48.0
37.8

4.8 (0.2-15.0)
6.8 (1.5-15.0)
4.5 (0.3-13.5)

29.4 (27.6 to 31.3)
21.2 (20.3 to 22.1)
18.2 (17.5 to 19.0)

<.001

5647
6324
6066

4536
5324
5244

48.4
42.4
37.0

7.5 (1.5-15.0)
4.5 (0.8-15.0)
4.5 (0.3-10.5)

21.1 (20.1 to 22.3)
19.5 (18.5 to 20.5)
18.3 (17.3 to 19.3)

<.001

6216
10 031
4247

5051
8255
3558

34.8
46.6
44.9

4.0 (0.0-10.5)
6.0 (1.5-15.0)
4.5 (0.9-15.0)

20.0 (19.0 to 21.1)
21.7 (20.9 to 22.5)
19.4 (18.2 to 20.6)

.004

432
8836
8048
3178

357
7227
6664
2616

32.2
44.5
44.1
35.2

2.3 (0.0-10.5)
5.1 (0.7-15.0)
4.5 (1.3-15.0)
4.5 (0.3-10.5)

17.9 (14.4 to 21.8)
21.2 (20.3 to 22.0)
20.3 (19.5 to 21.2)
20.8 (19.4 to 22.2)

.29

18 931
1563

15 493
1371

43.2
35.5

4.5 (0.7-15.0)
4.5 (0.3-10.5)

21.2 (20.6 to 21.8)
14.8 (13.1 to 16.6)

<.001

5548
3936

4420
3060

38.2
41.8

4.5 (0.3-14.9)
4.5 (0.9-15.0)

22.8 (21.7 to 24.0)
26.0 (24.6 to 27.4)

<.001

7543
3591
3224
2723
3413

5753
2874
2673
2500
3064

43.5
42.4
42.5
40.7
42.8

4.5 (0.7-15.0)
4.5 (0.6-14.9)
4.5 (1.1-14.8)
4.5 (0.5-12.3)
4.5 (0.3-15.0)

27.0 (26.0 to 28.0)
24.8 (23.4 to 26.3)
20.5 (19.1 to 22.0)
10.0 (8.9 to 11.2)
11.8 (10.7 to 12.9)

<.001

2776
3347
5566
8805

1482
2776
5206
7400

40.4
42.4
38.8
45.9

4.5 (0.3-12.5)
4.5 (0.3-14.5)
4.5 (0.3-10.5)
6.1 (1.5-15.0)

54.3 (52.3 to 56.2)
21.0 (19.6 to 22.4)
5.9 (5.3 to 6.5)
20.2 (19.3 to 21.0)

<.001

719
2183
3767
1296
12 529

423
1521
3075
1200
10 645

40.1
41.6
40.3
39.0
44.0

4.5 (1.5-10.5)
4.5 (0.8-10.5)
4.5 (0.7-10.5)
4.5 (0.8-10.5)
4.8 (0.4-15.0)

46.1 (42.3 to 49.8)
38.5 (36.4 to 40.5)
22.5 (21.2 to 23.9)
11.8 (10.1 to 13.6)
16.7 (16.0 to 17.3)

<.001

7615
8559
4320

6706
6942
3216

40.1
43.3
45.9

4.5 (0.3-10.5)
4.5 (0.7-14.6)
7.2 (1.5-18.1)

19.8 (18.9 to 20.7)
20.6 (19.8 to 21.5)
22.6 (21.3 to 23.9)

.02

a

Percentage of adherence to the recommended physical activity guidelines,  at least 500 MET-minutes (8.3 MET-hours) per week. CI ¼ confidence interval; IQR ¼ inter-

quartile range; LTPA ¼ leisure-time physical activity; MET-h/week ¼ metabolic-equivalent hours per week.
b

Statistical differences across survival rates (2-sided P values) were estimated by the log-rank test and corrected for multiple comparisons by controlling the false-discovery rate.

c

Moderate defined as >0 to 1 (women) or >0 to 2 (men) drinks per day and heavy defined as >1 (women) or >2 (men) drinks per day.

d

Localized, regional, and distant stages included stage I and II, stage III, and stage IV, respectively.

e

Time interval from physical activity assessment to lung cancer diagnosis.

and
was
.003
cer,

2, available online). Clear evidence of additive interaction
found by stage (Pinteraction ¼ .008 for all-cause mortality and
for lung cancer–specific mortality). For localized lung canprediagnosis LTPA of at least 8.3 MET-h/week was

associated with 20% lower mortality (HR ¼ 0.80, 95% CI ¼ 0.67 to
0.97, for all-causes, and HR ¼ 0.80, 95% CI ¼ 0.65 to 0.99, for lung
cancer). Meanwhile, overall associations were weaker for
regional stage lung cancer (HR ¼ 0.89, 95% CI ¼ 0.77 to 1.02, and
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Vocational school/some college
University graduation
Smoking status
Never
Former
Current
Smoking pack-years in smokers
<30
30-49
50
Alcohol consumptionc
None
Moderate
Heavy
Body mass index, kg/m2
<18.5
18.5-24.99
25.0-29.99
30.0
History of diabetes
No
Yes
Hormone therapy in women
No
Yes
Histological type
Adenocarcinoma
Squamous cell carcinoma
Other non-small cell carcinoma
Small cell carcinoma
Unspecified
Tumor staged
Localized
Regional
Distant
Unknown
Tumor grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
From baseline to diagnosis, ye
<5
5-9
10

No. of cases

5-year survival

Meet the
guideline, (%)a

7297/8749
21.1 (20.2 to 22.0)
0.96 (0.91 to 1.01)
0.97 (0.91 to 1.02)
654/1170
54.3 (51.3 to 57.3)
0.92 (0.77 to 1.10)
0.93 (0.78 to 1.12)
1176/1419
22.3 (20.1 to 24.5)
0.94 (0.82 to 1.08)
0.94 (0.82 to 1.09)
2174/2315
5.6 (4.7 to 6.6)
0.98 (0.89 to 1.07)
0.98 (0.90 to 1.08)

226/485
52.9 (47.9 to 57.6)
1 (Referent)
1 (Referent)
397/510
20.4 (16.9 to 24.1)
1 (Referent)
1 (Referent)
995/1093
6.3 (4.9 to 7.8)
1 (Referent)
1 (Referent)

>0 to <8.3

2380/3008
18.1 (16.7 to 19.6)
1 (Referent)
1 (Referent)

None

2037/2158
6.0 (5.1 to 7.1)
0.97 (0.89 to 1.06)
0.98 (0.89 to 1.07)

1203/1418
19.8 (17.8 to 22.0)
0.87 (0.76 to 1.00)
0.89 (0.77 to 1.02)

602/1121
54.8 (51.7 to 57.8)
0.79 (0.66 to 0.95)
0.80 (0.67 to 0.97)

7187/8737
21.2 (20.3 to 22.1)
0.92 (0.87 to 0.97)
0.93 (0.88 to 0.99)

8.3

.61
.73

.06
.17

.009
.02

.002
.01

Ptrendd

885/1048
10.0 (8.2 to 12.0)
1 (Referent)
1 (Referent)

332/480
25.6 (21.5 to 29.8)
1 (Referent)
1 (Referent)

165/473
60.1 (55.0 to 64.9)
1 (Referent)
1 (Referent)

1965/2822
23.7 (22.0 to 25.4)
1 (Referent)
1 (Referent)

None

1900/2252
10.7 (9.4 to 12.1)
1.03 (0.97 to 1.10)
1.03 (0.97 to 1.10)

945/1377
29.5 (27.1 to 32.1)
0.98 (0.86 to 1.11)
0.98 (0.86 to 1.11)

391/1152
66.2 (63.2 to 69.1)
0.84 (0.68 to 1.03)
0.84 (0.68 to 1.04)

5764/8267
28.5 (27.5 to 29.5)
0.99 (0.94 to 1.04)
1.00 (0.96 to 1.05)

>0 to <8.3

Ptrendd

.29
.63

.42
.46

.42
.51

.50
.53

8.3

5867/8328
27.4 (26.4 to 28.4)
0.98 (0.93 to 1.02)
0.99 (0.95 to 1.04)
405/1097
64.3 (61.2 to 67.2)
0.80 (0.65 to 0.99)
0.80 (0.65 to 0.99)
996/1353
25.4 (23.0 to 27.8)
0.93 (0.83 to 1.05)
0.95 (0.84 to 1.07)
1815/2113
10.4 (9.1 to 11.8)
1.04 (0.98 to 1.10)
1.04 (0.98 to 1.11)

Deaths from lung cancerc

Adjusted for age at diagnosis, sex, smoking status, smoking pack-years, race and ethnicity, education, alcohol consumption, history of diabetes, body mass index levels, hormone therapy in women, and histological type and

Adjusted for age at diagnosis, sex, smoking status, and smoking pack-years and stratified by cohort, year of lung cancer diagnosis, and time interval from leisure-time physical activity assessment to lung cancer diagnosis.

Patients missing cause of death were excluded from the analysis; death from other causes was treated as a competing risk.
Corrected for multiple comparisons by controlling the false-discovery rate.
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grade of lung cancer and stratified by cohort, year of lung cancer diagnosis, and time interval from leisure-time physical activity assessment to lung cancer diagnosis.

f

e

d

c

Activity Guidelines.

500 MET-min/wk (8.3 MET-h/week) was the level recommended for substantial health benefits based on the physical active guidelines such as the World Health Organization Global Recommendations and 2018 Physical

b

Localized, regional, and distant stages included stage I and II, stage III, and stage IV, respectively. Additive interactions were statistically significant: P interaction ¼ .008 for all-cause mortality and .003 for lung cancer–specific mortality. CI ¼ confidence interval; MET-h/week ¼ metabolic-equivalent hours per week.

a

Total cases
Deaths/cases, No.
5-year survival rate (95% CI), %
Hazard ratio (95% CI)e
Hazard ratio (95% CI)f
Localized lung cancer cases
Deaths/cases, No.
5-year survival rate (95% CI), %
Hazard ratio (95% CI)e
Hazard ratio (95% CI)f
Regional lung cancer cases
Deaths/cases, No.
5-year survival rate (95% CI), %
Hazard ratio (95% CI)e
Hazard ratio (95% CI)f
Distant lung cancer cases
Deaths/cases, No.
5-year survival rate (95% CI), %
Hazard ratio (95% CI)e
Hazard ratio (95% CI)f

Tumor stage

Deaths from all causes

Leisure-time physical activity (MET-h/week)b

Table 3. Association of prediagnosis leisure-time physical activity with all-cause and lung cancer–specific mortality among lung cancer patients by tumor stagea
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Discussion
In this pooled analysis of 20 494 incident lung cancer patients
from 11 prospective cohorts, regular participation in LTPA prior
to cancer diagnosis, particularly when meeting or exceeding the
minimum Physical Activity Guidelines, was associated with reduced hazards of mortality among lung cancer patients.
Notably, patients diagnosed with localized lung cancer showed
approximately 20% lower all-cause and lung cancer–specific
mortality when engaging in LTPA of at least 8.3 MET-h/week before diagnosis compared with inactivity. A statistically significant additive interaction by stage was suggested. Our findings
support a possible long-term benefit of habitual LTPA adhering
to the Physical Activity Guidelines. If confirmed, pretreatment
LTPA could be proposed as a possible stratification factor for future therapeutic trials, at least for early stage lung cancer
patients.
Currently, epidemiological evidence on survival benefits attributed to prediagnosis LTPA remains limited among lung cancer patients (8,9,11,12). In a recent systematic review and metaanalysis of all existing epidemiologic studies and trials (7), the
summary HR for lung cancer–specific mortality associated with
higher levels of prediagnosis PA was 0.81 (95% CI ¼ 0.75 to 0.87);
no data was available for all-cause mortality. Despite adding an
important piece of evidence, this finding was derived as a part
of 5 studies accessing multiple cancer sites, not focusing only

on lung cancer. Thus, overall numbers of lung cancer patients
and deaths were limited, and lung cancer–specific prognostic
and risk factors could not be properly considered. Several observational studies also showed the beneficial impact of prediagnosis PA on lung cancer mortality (13-15), in line with our
findings. For example, the b-Carotene and Retinol Efficacy Trial,
including 231 lung cancer cases and 141 deaths, found an inverse association of prediagnosis total PA with mortality only
among women who smoked heavily (13). The Women’s Health
Initiative study, analyzing 2148 lung cancer patients and 1 365
lung cancer deaths, reported 20%-32% lower lung-cancer mortality associated with at least 100 MET-minutes/week of exercise among postmenopausal women (14), with a dose-response
association for adenocarcinoma only. Recently, a hospitalbased, case-control study (579 cases with 560 total deaths and
481 lung cancer–specific deaths) reported that lifetime recreational physical inactivity was associated with 30%-40% increased mortality (HR ¼ 1.31, 95% CI ¼ 1.09 to 1.58, for all-cause
mortality, and HR ¼ 1.40, 95% CI ¼ 1.14 to 1.71, for lung cancer–
specific mortality) (15). Consistent with our findings, this study
observed a stronger inactivity–mortality association among
early stage lung cancer cases; no association was found for distant stage. Similarly, some cohort studies showed that higher
cardiorespiratory fitness levels prior to cancer diagnosis were
linked to a lower risk of death among lung cancer patients (3235). Nonetheless, most previous studies were limited to insufficient sample size, restricted to predominantly White populations, and lacked consideration of major prognostic factors,
subgroup variations, and potential competing risks of death.
Our large sample size, including 20 494 incident lung cancer
patients with different stage and histology and 16 864 deaths
from racially and ethnically diverse populations, detailed data
on clinical features of lung cancer, and enhanced scientific rigor
would overcome the previous limitations. Findings from this
pooled analysis suggest that the association of prediagnosis
LTPA with lung cancer survival could be modified by tumor
stage and histological type. Black patients appeared to have
lower HRs than others, although the test for interaction was not
statistically significant. Also, the overall associations remained
consistent across sex, smoking, BMI, and other factors potentially related to survival, adding a piece of epidemiologic evidence to a possible causal association.
PA has attracted much attention as a potential protective
factor against cancer-related deaths, recurrence, or metastasis
(4-6,36). During exercise, the body activates biological mechanisms which inhibit tumor growth, including modulation of carcinogenic factors (ie, inflammatory cytokines, insulin-like
growth factors, and other hormones) and enhancement in immune function and metabolic health (6). Long-term habitual PA
can lead to intratumoral adaptations, including improvements
in blood perfusion, immunogenicity, and immune cell infiltration (4,5), which help inhibit cancer progression. Given these biological benefits, it is possible that PA before initiation of
carcinogenesis may result in developing less aggressive tumors.
Furthermore, PA plays a crucial role in enhancing drug tolerance and efficacy, alleviating treatment-related adverse effects,
and reducing the likelihood of relapse and metastasis (4,36).
Regarding lung-specific benefits from PA, evidence indicates
that greater amounts of PA are associated with less lung function decline, better pulmonary functional capacity, and a lower
risk of chronic obstructive pulmonary disease (37-39). Indeed, a
recent systematic review of randomized-controlled trials has
reported that presurgery exercise interventions could substantially improve physical and pulmonary functions among lung
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HR ¼ 0.95, 95% CI ¼ 0.84 to 1.07, respectively), and null associations were found for distant stage (Table 3). Results from
random-effects meta-analyses yielded similar results as those
presented, with about 20% lower mortality among localized
cases who adhered to prediagnosis LTPA of at least 8.3 MET-h/
week (HR ¼ 0.80, 95% CI ¼ 0.66 to 0.98, for all-cause mortality;
Pheterogeneity ¼ .48; and HR ¼ 0.76, 95% CI ¼ 0.61 to 0.94, for lung
cancer–specific mortality; Pheterogeneity ¼ .50; Supplementary
Figures 3 and 4, available online). Exclusion of any cohort from
the main analysis one at a time had limited impacts on the
above-reported associations (Supplementary Table 2, available
online).
In stratified analyses of localized and regional-stage lung
cancer (Figures 1 and 2), we observed additive interactions
when jointly considering prediagnosis LTPA and histological
type (Pinteraction ¼ .04 for all-cause mortality and .003 for lung
cancer–specific mortality). Prediagnosis LTPA of at least 8.3
MET-h/week was associated with 21% lower all-cause mortality
for adenocarcinoma (HR ¼ 0.79, 95% CI ¼ 0.66 to 0.95). The overall
association pattern remained consistent across the potential
prognostic and risk factors (eg, race and ethnicity and BMI; all
Pinteraction > .05), but the magnitude of the associations attenuated when LTPA assessment was far from cancer diagnosis.
Notably, never-smokers also appeared to have survival benefits
from prediagnosis LTPA of at least 8.3 MET-h/week (HR ¼ 0.76,
95% CI ¼ 0.55 to 1.06, for all-cause mortality, and HR ¼ 0.79, 95%
CI ¼ 0.58 to 1.07, for lung cancer–specific mortality), but the
point estimates failed to reach statistical significance because
of the small sample size.
A series of sensitivity analyses showed a similar pattern of
the associations (data not shown). Further analyses separating
the moderately active (8.3-16.0 MET-h/week) and the highly active (16.0 MET-h/week) groups showed little evidence that the
latter was more strongly related to lung cancer survival; however, the risk estimate was unstable because of its insufficient
sample size (data not shown).
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No.of deaths
≥ 8.3
None

Adjusted
HR (95% CI)

P Interaction

966
839

398
225

0.77 (0.66-0.89)
0.99 (0.83-1.18)

.71

1139
666

313
310

0.86 (0.74-1.00)
0.87 (0.74-1.03)

.34

94
43
1654

171
94
347

0.91 (0.67-1.22)
0.68 (0.44-1.06)
0.86 (0.75-0.98)

.97

847
958

431
192

0.94 (0.81-1.08)
0.76 (0.64-0.91)

.97

180
832
793

98
166
359

0.76 (0.55-1.06)
0.80 (0.66-0.97)
0.92 (0.79-1.07)

.71

455
937
413

317
181
125

0.91 (0.77-1.09)
0.86 (0.71-1.04)
0.77 (0.60-0.98)

.97

769
780
256

306
198
119

0.83 (0.70-0.98)
0.93 (0.77-1.12)
0.78 (0.60-1.02)

.97

1672
133

562
61

0.86 (0.77-0.97)
0.95 (0.60-1.50)

.75

363
303

225
85

0.88 (0.72-1.08)
0.94 (0.70-1.26)

.79

685
434
272
220

230
164
98
72

0.79 (0.66-0.95)
0.84 (0.67-1.06)
0.90 (0.68-1.19)
0.93 (0.65-1.32)

.04

378
585

95
156

0.82 (0.62-1.07)
0.92 (0.74-1.13)

.71

827
785
193

352
223
48

0.87 (0.74-1.01)
0.80 (0.67-0.96)
1.10 (0.75-1.60)

.90

0

0.5
1
1.5
Adjusted HR (95% CI)

2

Figure 1. Prediagnosis leisure-time physical activity and all-cause mortality among lung cancer patients: stratified analyses of localized and regional stage cases. HRs
(95% CIs) for 8.3 MET-h/week vs none were shown after adjusting for age at diagnosis, sex, smoking status, smoking pack-years, race and ethnicity, education, alcohol
consumption, history of diabetes, BMI levels, hormone therapy in women, histological type, tumor stage, and grade of lung cancer and stratifying by cohort, year of
lung cancer diagnosis, and time interval from leisure-time physical activity assessment to lung cancer diagnosis. Interaction (additive) refers to global P value for relative excess risk due to interaction between prediagnosis leisure-time physical activity and each stratification variable. All P values were corrected for multiple comparisons by controlling the false-discovery rate. All statistical tests were 2-sided. Error bars represent the 95% CIs. BMI ¼ body mass index; CI ¼ confidence interval; HR ¼
hazard ratio; MET-h/week ¼ metabolic-equivalent hours per week.

cancer patients and reduce postsurgery complications (40). In
our study, the association of prediagnosis LTPA appeared to be
stronger when exposure was measured closer to diagnosis,
lending some support to the mechanisms mentioned above.
Existing biological evidence and our epidemiological observations suggest that habitual LTPA may improve lung cancer survivorship, especially for early stage lung cancer. However, we

did not find any statistically significant association with distant
stage cancer. We speculate that the high fatality rate and short
survival time for late stage lung cancer made it difficult for us to
detect a moderate association with prediagnosis LTPA, if one
exists.
Our study has several strengths. This is the largest prospective investigation on the association of prediagnosis LTPA with
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≥ 8.3 MET-hr/wk vs. none
Age at lung cancer diagnosis
<70 years
≥70 years
Sex
Men
Women
Race and ethnicity
Asian
Black
White
Education
≤High school graduation
>High school graduation
Smoking status
Never
Former
Current
Alcohol consumption
None
Moderate
Heavy
Obesity status
≤Normal weight, BMI<25
Overweight, 25≤BMI<30
Obese, BMI≥30
History of diabetes
No
Yes
Hormone therapy in women
No
Yes
Histological type
Adenocarcinoma
Squamous cell carcinoma
Other non-small cell carcinoma
Small cell carcinoma
Tumor grade
Well/moderately differentiated
Poorly & undifferentiated
Time from baseline to diagnosis
< 5 years
5-9 years
≥ 10 years
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No.of deaths
≥ 8.3
None

Adjusted
HR (95% CI)

P Interaction

793
608

331
166

0.81 (0.71-0.93)
1.03 (0.87-1.24)

.23

893
508

253
244

0.91 (0.79-1.05)
0.93 (0.79-1.10)

.23

89
28
1272

162
73
257

0.91 (0.70-1.18)
0.54 (0.35-0.85)
0.91 (0.80-1.03)

.66

666
735

348
149

0.97 (0.85-1.12)
0.76 (0.64-0.90)

.89

143
611
647

87
119
291

0.79 (0.58-1.07)
0.87 (0.71-1.06)
0.95 (0.82-1.10)

.66

352
719
330

252
139
106

0.99 (0.84-1.18)
0.91 (0.76-1.10)
0.74 (0.60-0.91)

.89

620
592
189

250
162
85

0.94 (0.79-1.11)
0.88 (0.74-1.04)
0.86 (0.66-1.13)

.66

1297
104

455
42

0.89 (0.80-1.00)
1.09 (0.73-1.63)

.66

284
224

184
60

0.94 (0.77-1.14)
0.97 (0.70-1.35)

.66

541
320
211
190

187
131
77
61

0.86 (0.72-1.04)
0.84 (0.68-1.04)
0.90 (0.70-1.17)
0.94 (0.71-1.25)

.003

280
458

68
125

0.95 (0.71-1.26)
0.86 (0.71-1.04)

.42

658
620
123

278
181
38

0.97 (0.84-1.13)
0.83 (0.70-0.98)
0.94 (0.65-1.36)

.65

0

0.5

1

1.5

2

Adjusted HR (95% CI)
Figure 2. Prediagnosis leisure-time physical activity and lung cancer–specific mortality among lung cancer patients: stratified analyses of localized and regional stage
cases. HRs (95% CIs) for 8.3 MET-h/week vs none were shown after adjusting for age at diagnosis, sex, smoking status, smoking pack-years, race and ethnicity, education, alcohol consumption, history of diabetes, BMI levels, hormone therapy in women, histological type, tumor stage, and grade of lung cancer and stratifying by cohort, year of lung cancer diagnosis, and time interval from leisure-time physical activity assessment to lung cancer diagnosis. For the lung-cancer mortality analyses,
cases missing cause of death were excluded from the analysis, and death from other causes was treated as a competing risk. Interaction (additive) refers to global P
value for relative excess risk because of interaction between prediagnosis leisure-time physical activity and each stratification variable. All P values were corrected for
multiple comparisons by controlling the false-discovery rate. All statistical tests were 2-sided. Error bars represent the 95% CIs. BMI ¼ body mass index; CI ¼ confidence
interval; HR ¼ hazard ratio; MET-h/week ¼ metabolic-equivalent hours per week.

lung cancer survival. We used individual participant data of
more than 20 000 incident lung cancer patients from diverse
populations. Our prospective design, large sample size, and extensive information on a wide range of clinical characteristics,
smoking history, and other lifestyle factors enabled

comprehensive analyses. All the analyses were controlled for or
stratified by major prognostic and risk factors and considered
potential competing risks of death, which enhanced the scientific rigor of our study. Nonetheless, several limitations should
be acknowledged. First, because of a lack of information, we
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≥ 8.3 MET-hr/wk vs. none
Age at lung cancer diagnosis
<70 years
≥70 years
Sex
Men
Women
Race and ethnicity
Asian
Black
White
Education
≤High school graduation
>High school graduation
Smoking status
Never
Former
Current
Alcohol consumption
None
Moderate
Heavy
Obesity status
≤Normal weight, BMI<25
Overweight, 25≤BMI<30
Obese, BMI≥30
History of diabetes
No
Yes
Hormone therapy in women
No
Yes
Histological type
Adenocarcinoma
Squamous cell carcinoma
Other non-small cell carcinoma
Small cell carcinoma
Tumor grade
Well/moderately differentiated
Poorly & undifferentiated
Time from baseline to diagnosis
< 5 years
5-9 years
≥ 10 years
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